Form 8-K - Current report:
SEC Accession No. 0000950170-25-069785
Filing Date
2025-05-13
Accepted
2025-05-13 07:06:16
Documents
13
Period of Report
2025-05-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20250508.htm   iXBRL 8-K 58846
2 EX-99.1 axsm-ex99_1.htm EX-99.1 24064
3 GRAPHIC img36028404_0.jpg GRAPHIC 66512
  Complete submission text file 0000950170-25-069785.txt   294216

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT axsm-20250508.xsd EX-101.SCH 23858
15 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20250508_htm.xml XML 4543
Mailing Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 25937098
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)